Thus, inhibition of hidden oncogenic signaling pathways in DIPG such as TβRI that are not limited to ACVR1 itself may provide alternative entry points for DIPG therapeutics. This evidence concerns the gene TGFBR1 and diffuse intrinsic pontine glioma.